Human-centric preclinical models for CAR T cell therapy in solid tumors: Where patient-derived organoids fit.

Patient-derived organoids enable functional evaluation of CAR T cell therapies in solid tumors, capturing tumor complexity and heterogeneity crucial for clinical success.

• Why it matters: Current preclinical models fail to fully replicate human tumor biology, limiting the translation of CAR T cell therapies for solid tumors and risking ineffective treatments.
• What they did: Researchers highlight how PDOs preserve key tumor features and support testing of CAR T cell targets, resistance, safety, and next-generation approaches, complementing existing models.
• The result: Using PDOs advances preclinical evaluation, potentially accelerating the development of effective CAR T cell therapies for solid tumors and improving patient outcomes.